Study on the Effects of 2X-121 for Treating Recurrent, Advanced Ovarian Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of advanced ovarian, fallopian tube, or primary peritoneal cancer with specific types of cell characteristics.
• Cancer must have returned within 6 months after the last platinum-based chemotherapy or be ineligible for such treatment.
• Have received no more than one previous treatment for platinum-resistant cancer.
• Have measurable cancer that can be seen on a CT scan or MRI.
• Be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of more than 16 weeks.
• Have recovered from any previous treatments or surgeries.
• Meet specific blood and organ function criteria based on lab tests.
• Provide a tumor sample from the current relapse if possible.
• Women of childbearing potential must have a negative pregnancy test and use effective contraception during and for six months after the study.

Exclusion Criteria

• Cancer that progressed during the last platinum-based chemotherapy.
• Currently receiving other cancer treatments or investigational drugs.
• Have another type of cancer, except for certain early-stage cancers that are considered cured.
• Have an active infection requiring antibiotics.
• Have known HIV or active hepatitis B or C.
• Have significant heart disease or recent heart events.
• Have conditions or take medications that could interfere with the study.
• Have difficulty taking oral medication or have digestive issues that affect drug absorption.
• Require immediate treatment for symptoms or complications of cancer.
• Cannot be regularly followed up due to personal circumstances.
• Are closely related to or dependent on the study sponsor or investigator.
• Have fluid buildup in the abdomen requiring drainage within two weeks before joining the study.